May 11, 2009
The Food and Drug Administration announced today the approval of Vetoryl (trilostane) Capsules, a new drug for the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism, commonly known as Cushing’s disease.’ Vetoryl, a new molecular entity, is the first drug approved to treat both pituitary- and adrenal-dependent Cushing’s disease in dogs.’ Continue reading FDA approves drug to treat cushing’s disease